Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma.

Integr Cancer Ther · 2021 · PMC8743966 · PMID 33719631

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

only marginally significantP = .06so close (0.05 < p ≤ 0.1)

However, results have been mixed as when the peptide vaccine gp100 was combined with high dose IL-2, there was a higher median OS as compared to IL-2 alone (17.8 months vs 11.1 months), but this was only marginally significant ( P = .06). 69 Similarly, anti-CTLA-4 antibody ipilimumab was evaluated with peptide vaccine gp100, was described earlier in this review.

also in 5,072 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.